Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use and ensure optimum activity.
The abstract entitled: ‘This Drug for That Bug: Really? An Evidence-Based Discussion of Antimicrobial Activity Relevant to Antimicrobial Stewardship‘ was presented at IDWeek 2022, 19-23 October 2022.
Interviews available in this series:
Isavuconazole – a good treatment option for Candida species?
Linezolid as a treatment option for MRSA bacteraemia
Questions:
- What are the advantages and limitations of the use of ceftriaxone for the treatment of methicillin-susceptible staphylococcus aureus (MSSA)?
- What high quality data exists to support the use of ceftriaxone, and how can we ensure optimum activity?
Disclosures: Kayla Stover Hielscher has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
